Skip to main content
SpringerLink
Log in

Afatinib

Various toxicities and drug resistance following off-label treatment: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Sehgal K, et al. Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations. Oncologist 26: 281-287, No. 4, Apr 2021. Available from: URL: http://doi.org/10.1002/onco.13537

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Afatinib. Reactions Weekly 1880, 22 (2021). https://doi.org/10.1007/s40278-021-04856-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-021-04856-2

Search

Navigation